• 1
    Kirchhoff T, Kauff ND, Mitra N et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004; 10: 291821
  • 2
    Gallagher DJ, Pal P, Kirchhoff T et al. Correlation of BRCA2 mutation and prostate cancer phenotype. Proc Am Soc Clin Oncol Genitourinary Symp 2009; abstr 20
  • 3
    Thompson D, Easton DF, Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94: 135865
  • 4
    Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 14018
  • 5
    Gayther SA, de Foy KA, Harrington P et al. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res 2000; 60: 45138
  • 6
    Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283: 22605
  • 7
    Rubin SC, Blackwood MA, Bandera C et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 1998; 178: 6707
  • 8
    Kauff ND. Is it time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer? J Clin Oncol 2008; 26: 910
  • 9
    Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008; 26: 205
  • 10
    Rennert G, Bisland-Naggan S, Barnett-Griness O et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357: 11523
  • 11
    Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006; 25: 586474
  • 12
    Mani RS, Tomlins SA, Callahan K et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009; 326: 1230
  • 13
    Luedeke M, Linnert CM, Hofer MD et al. Predisposition for TMPRSS2–ERG fusion in prostate cancer by variants in DNA repair genes. Cancer Epidemiol Biomarkers Prev 2009; 18: 30305
  • 14
    Tan DS, Rothermundt C, Thomas K et al. ‘BRCAness’ syndrome in ovarian cancer: a case–control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26: 55306
  • 15
    Byrski T, Gronwald J, Huzarski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 3759
  • 16
    Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006; 5: 10017
  • 17
    Quinn JE, Kennedy RD, Mullan PB et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63: 62218
  • 18
    Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol 2003; 22: 116973
  • 19
    Mullan PB, Quinn JE, Gilmore PM et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001; 20: 612331
  • 20
    Tassone P, Blotta S, Palmieri C et al. Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents. Int J Oncol 2005; 26: 125763
  • 21
    Zhou C, Smith JL, Liu J. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 2003; 22: 2396404
  • 22
    Sylvain V, Lafarge S, Bignon YJ. Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol 2002; 20: 84553
  • 23
    Kurebayashi J, Yamamoto Y, Kurosumi M et al. Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. Anticancer Res 2006; 26: 695701
  • 24
    Byrski T, Gronwald J, Huzarski T et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008; 108: 28996
  • 25
    Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 150212
  • 26
    Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 2425
  • 27
    Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 34617
  • 28
    Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98: 51621
  • 29
    Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 151320
  • 30
    Miglietta L, Cannobbio L, Boccardo F. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Anticancer Res 1995; 15: 28258
  • 31
    Canobbio L, Guarneri D, Miglietta L, Decensi A, Oneto F, Boccardo F. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur J Cancer 1993; 29A: 20946
  • 32
    Jungi WF, Bernhard J, Hürny C et al. Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK). Support Care Cancer 1998; 6: 4628
  • 33
    Oh WK, Tay MH, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 2007; 109: 47786
  • 34
    Oh WK, Halabi S, Kelly WK et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 2003; 98: 25928
  • 35
    Oh WK, Hagmann E, Manola J et al. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005; 11: 2849
  • 36
    Papandreou CN, Daliani DD, Thall PF et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002; 20: 307280
  • 37
    Berry W, Friedland D, Fleagle J et al. A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. Clin Genitourin Cancer 2006; 5: 1317
  • 38
    Kelly WK, Curley T, Slovin S et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001; 19: 4453
  • 39
    Urakami S, Igawa M, Kikuno N et al. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 2002; 168: 244450
  • 40
    Solit DB, Morris M, Slovin S et al. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer 2003; 98: 18428
  • 41
    Sternberg CN, Petrylak DP, Sartor O et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 54318
  • 42
    Tutt A, Robson M, Garber JE et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009; 27 (Suppl.): abstr CRA501
  • 43
    Audeh MW, Penson RT, Friedlander M et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 2009; 27 (Suppl.): abstr 5500
  • 44
    McCabe N, Turner NC, Lord CJ et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 810915
  • 45
    Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 9137
  • 46
    Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 91721
  • 47
    Mendes-Pereira AM, Martin SA, Brough R et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1: 31522
  • 48
    Yoshimoto M, Cutz JC, Nuin PA et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 2006; 169: 12837
  • 49
    Cairns P, Okami K, Halachmi S et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997; 57: 49975000
  • 50
    Dong JT, Sipe TW, Hyytinen ER et al. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 1998; 17: 197982
  • 51
    Verhagen PC, van Duijn PW, Hermans KG et al. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 2006; 208: 699707
  • 52
    Suzuki H, Freije D, Nusskern DR et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998; 58: 2049
  • 53
    Yoshimoto M, Cunha IW, Coudry RA et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007; 97: 67885
  • 54
    Fong PC, Boss DS, Carden CP et al. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study. J Clin Oncol 2008; 26 (Suppl.): abstr 5510
  • 55
    Gallagher DJ, Gaudet MM, Pal P et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010; 16: 211521